Ponesimod
Ponesimod is an oral sphingosine-1-phosphate (S1P) receptor modulator used to treat adults with active relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS, depending on local approval. It works by selectively binding to S1P₁ receptors, retaining certain lymphocytes in lymph nodes and reducing their migration into the central nervous system, where they can contribute to inflammation and nerve damage. Ponesimod is available as oral tablets, with treatment initiated using a gradual dose-titration schedule before reaching the maintenance dose. Common side effects include upper respiratory tract infections, elevated liver enzymes, hypertension, and dizziness. Important risks include reduced heart rate, infections, macular oedema, liver injury, and respiratory effects. Treatment requires medical supervision, with appropriate cardiac assessment, blood tests, infection screening, and eye examinations as clinically indicated.
Ponesimod was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Ponesimod, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Ponesimod from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Ponesimod, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
